Farmers and growers have been using glyphosate-based herbicides safely and effectively to control weeds for more than 40 years. These products continue to play a critical role in helping farmers manage weeds and sustainably deliver crops to markets around the world.
The litigation over glyphosate primarily stems from one place: an opinion by a group called IARC. IARC is not a regulatory authority and did not conduct any original scientific studies. Yet in 2015, after IARC classified glyphosate as a “probable carcinogen,” trial attorneys in the U.S. began running advertisements to recruit plaintiffs for lawsuits against Monsanto, the manufacturer of many glyphosate-based herbicides (i.e., RoundupTM-branded herbicides). These lawsuits rely heavily on IARC’s classification, which has many significant limitations and flaws and runs counter to an extensive body of science supporting glyphosate’s safe use. More than four years after reaching its opinion, leading pesticide regulators around the world continue to conclude that glyphosate is not carcinogenic and that glyphosate-based herbicides are safe when used as directed.
On September 1, 2022, a defense verdict was issued in the Alesi trial in St. Louis County, Missouri, the fifth consecutive win for Monsanto in this litigation. The next trial is Ferro in St. Louis County, which is scheduled to begin on October 24, 2022.
Bayer will vigorously defend its products based on the strong body of science that confirms glyphosate and glyphosate-based products are safe when used as directed and that glyphosate does not cause cancer.
The trial schedule continues to remain fluid and subject to change based on multiple factors, including the COVID pandemic, the schedules of courts and parties, and the continued efforts by parties to resolve cases.